MARATTO

article · Afro-Egyptian Journal of Infectious and Endemic Diseases

COVID-19: Virology, Pathogenesis and Potential Therapeutics

202022 citationsOpen accessZagazig University

Abstract

Nowadays, the coronavirus epidemic represents a major threat to the human being, represented by great numbers of deaths and wide world life disrupt. COVID-19 virus, is not only representing a threat to the life of human being, but also to the economic activities that nearly stopped in many countries due to the partial to complete closure of life activities in order to control the wide spread of virus infections. In these extraordinary and unprecedented critical times of human being life, it is essential to review and discus the virus epidemic in trial to suggest an idea that might be beneficial to researchers to find out an exit from this dark tunnel and to prevent as possible epidemic recurrence. Many attempts of management protocols and trials all over the world, nearly failed until now to control the wide spread and the high incidence of morbidity and mortality of this viral infection. In this review, we highlight the virology and pathogenesis of epidemic and possible used therapeutics in a simplified and concise form to be easily understood and available for healthcare members and even general population. This might help in control and eradication of the current epidemic.

Research topics

  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 diagnosis using AI

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/aeji.2020.93432

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.